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Synergistic association 
of high‑sensitivity C‑reactive 
protein and body mass 
index with insulin resistance 
in non‑diabetic adults
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Epidemiological evidence has indicated that inflammatory markers and obesity are strongly correlated 
with insulin resistance (IR). However, there is a paucity of studies assessing the complex interaction 
between elevated hs‑CRP and body mass index (BMI), particularly among Asians. This study 
investigated the additive interaction between hs‑CRP and BMI on IR, using cross‑sectional data from 
the 7th Korea National Health and Nutrition Examination Survey (2016–2018). A total of 5706 men 
and 6707 women aged 20 years or older were evaluated, and a multiple logistic regression analysis 
was used to assess the association of serum hs‑CRP and BMI with IR, as measured by the triglyceride‑
glucose index (TyG index). Sex‑specific median values were used to dichotomise the continuous TyG 
index variable into insulin‑sensitive and IR categories. Biological interaction was evaluated using the 
Relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), and 
synergy index (SI). The joint effects of high hs‑CRP and overweight/obesity on IR were greater than 
would be expected from the effects of the individual exposures alone. Relative to those with low 
hs‑CRP and BMI < 23, having both exposures was related to increased IR with an adjusted OR of 2.97 
(95% CI 2.50–3.52) in men and 3.08 (95% CI 2.67–3.56) in women with significant additive interactions. 
These findings demonstrate that IR prevention strategies that reduce both systematic inflammation 
and BMI may exceed the expected benefits based on targeting these risk factors separately.
Insulin resistance (IR) is a condition characterised by the inability of the peripheral tissues to properly utilize 
endogenous insulin to maintain glucose homoeostasis. Several lines of evidence suggest that IR is an underlying 
cause of a range of health outcomes, including cardiovascular  diseases1,2, cognitive  dysfunction3,  frailty4, and 
certain  cancers5,6. IR has also been established as a major feature of the development and pathophysiology of 
type 2 diabetes (T2DM)7,8. It represents one of the leading causes of premature mortality in the adult population 
globally, with an estimated 1.6 million deaths caused by  diabetes9. Further, the International Diabetes Federation 
(IDF) projected that by 2045, the number of people diagnosed with diabetes will increase by 51%, to 700  million10. 
Consequently, the disease burden associated with diabetes will continue to escalate over the next decades.
In light of the high morbidity and mortality rates associated with T2DM, prominent scientific efforts have 
been directed towards identifying possible risk factors for insulin resistance. Accumulating experimental and 
epidemiologic evidence has shown that inflammatory processes are linked to impaired glucose metabolism. 
In particular, the systemic inflammatory biomarker C-reactive protein (CRP), when measured in the blood 
with high sensitivity assay, has been reported to highly correlate with insulin resistance in  diabetic11 and non-
diabetic  individuals12,13. IR is known to be associated with chronic inflammation, which is induced by various 
pro-inflammatory cytokines and oxidative stress biomarkers, notably interleukin-1 beta (IL-1β), interleukin-6 
(IL-6), and  adipocytokines14,15. Chronic exposure to elevated levels of pro-inflammatory biomarkers stimulates 
the activation of cytokine signalling pathways, which prevent the activation of insulin signalling receptors in 
β-cells of pancreatic islets. In addition, obesity is closely related to insulin resistance. Furthermore, dysfunctional 
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lipid metabolism accompanies obesity and can negatively regulate insulin action. Few studies, however, have 
assessed the combined association of increased hs-CRP and body mass index (BMI) on insulin resistance, 
particularly in Asian populations. Therefore, we sought to investigate this relationship in a large representative 
sample of non-diabetic adults from the 2016–2018 Korea National Health and Nutrition Examination Survey.
Results
Participant characteristics. The characteristics of 5706 men and 6707 women, according to insulin resist-
ance status, who were included in this study are shown in Table 1. Among all participants, 45.97% were men, 
and the prevalence of insulin resistance was 50.04% and 50.02% in men and women, respectively. In both men 
and women, the insulin-resistant group had a significantly higher proportion of overweight/obese individuals, 
smokers, and drinkers than the insulin-sensitive group. Furthermore, a lower prevalence of hypertension and 
dyslipidemia was noted in the insulin-sensitive group. Table 2 outlines the general characteristics of participants 
with serum hs-CRP levels above and below the median value. Overall, individuals with high hs-CRP were more 
likely to be older, rural residents, of lower household incomes, less educated, overweight/obese, current smokers, 
and drinkers than those with hs-CRP values below the median. Moreover, individuals with high hs-CRP levels 
had a higher prevalence of hypertension and dyslipidemia and a lower physical activity level than their counter-
parts with lower hs-CRP levels.
Association of insulin resistance with hs‑CRP levels and BMI. The age- and multivariable-adjusted 
odds ratios (ORs) and 95% confidence intervals (CI) for the associations of hs-CRP level or BMI with insulin 
resistance by sex are shown in Table 3. In the multivariable-adjusted analyses, serum hs-CRP and BMI were inde-
pendently associated with insulin resistance, after controlling for age, region, monthly household income, edu-
cational level, smoking status, drinking status, physical activity, hypertension, dyslipidemia, and self-reported 
diagnosis of cardiovascular diseases. In the comparison of high versus low hs-CRP levels, elevated serum hs-CRP 
levels, above the median, were associated with a 1.57-fold (OR 1.57, 95%CI 1.39–1.76) and 1.84-fold (OR 1.84, 
95% CI 1.65–2.05) increased OR of IR in men and women, respectively. Furthermore, in both men and women, 
higher BMI was associated with higher odds of being insulin resistant. Men with a BMI ≥ 23.0 had a 2.26-fold 
greater OR of becoming insulin resistant, compared to the reference group (OR: 2.26, 95% CI 1.98.04–2.57). The 
corresponding adjusted OR for IR in women was 2.14 (95% CI 1.91–2.39).
Synergistic interaction of elevated hs‑CRP levels and BMI on insulin resistance. As shown in 
Fig. 1, we found a statistically significant synergistic interaction between hs-CRP and body mass index on insulin 
resistance. In the multivariable analysis and using men with low hs-CRP and BMI < 23 as the reference category, 
BMI ≥ 23 alone or high hs-CRP alone were associated with increased odds of insulin resistance (OR 1.98; 95% CI 
1.66–2.37 and OR 1.27; 95% CI 1.03–1.58, respectively). Furthermore, having both risk factors greatly enhanced 
the OR of insulin resistance to 2.97 (95% CI 2.50–3.52). The estimated RERI was 0.72 (95% CI 0.30–1.12), indi-
cating a synergistic interaction of hs-CRP and overweight/obesity on insulin resistance. In other words, the OR 
for the concurrence of obesity and elevated hs-CRP levels on insulin resistance was beyond the sum of the odds 
ratios associated with their individual effect. In addition, the attributable proportion (AP) revealed that 24% of 
the total odds of being insulin resistance was related to the interaction between elevated hs-CRP and BMI. Addi-
tionally, the synergy index (SI 1.58, 95% CI 1.15–1.98) also confirmed a synergistic interaction. Among women, 
the OR for the combination of high hs-CRP and BMI ≥ 23 (OR 3.08; 95% CI 2.67–3.56) was greater than the ORs 
for high hs-CRP and BMI < 23 (OR 1.45; 95% CI 1.24–1.69) and low hs-CRP and BMI ≥ 23 (OR 1.72; 95% CI 
1.46–2.03). The RERI for insulin resistance was statistically significant in women (RERI 0.91; 95% CI 0.49–1.33). 
The AP was 0.29 (95% CI 0.13–0.72), and the SI was 1.78 (95% CI 1.35–2.20).
Sensitivity analysis. In order to evaluate the robustness of these associations, a sensitivity analysis was 
conducted, in which we excluded participants with hypertension, dyslipidemia, and self-reported diagnosis of 
cardiovascular diseases. As shown in Supplementary Table S1, the magnitude and direction of the association 
remained essentially unchanged in the sensitivity analysis. However, due to the smaller sample size the statisti-
cal power was limited for the interaction analyses, and additive interaction measures did not reach statistical 
 significance16.
Discussion
In this population-based cross-sectional study of Korean non-diabetic participants aged 20 years or older, we 
found that individuals with elevated hs-CRP levels were at significantly higher odds of having insulin resistance, 
and that these associations persisted, even after adjusting for other relevant socio-demographic and health-related 
variables. Thus, our study confirms that systemic inflammation due to high hs-CRP levels has an independent 
effect on insulin resistance, as estimated by the TyG index.
The euglycemic hyperinsulinemic clamp method is considered the gold standard for estimating IR; however, 
because it is expensive and invasive, other surrogate IR indices have been developed based on anthropometric 
or biochemical parameters that are routinely collected in clinical practise. One such measure is the TyG index, 
which has been previously shown to be a simple, efficient, and clinically useful surrogate marker of IR. Two recent 
studies have shown that the TyG index is closely correlated with the homoeostasis model assessment of insulin 
resistance index (HOMA-IR)17,18. Moreover, other studies have reported that the TyG index value is superior for 
predicting IR to that of HOMA-IR18–20.
Elevated serum hs-CRP levels provide a sensitive marker of subclinical inflammation. Our finding of a posi-
tive association between serum hs-CRP levels and IR has been supported by several studies that have reported 
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an association between CRP concentrations and surrogate measures of insulin resistance such as HOMA-IR and 
quantitative insulin sensitivity check index (QUICKI)21–23. The longitudinal cohort from the Bogalusa Heart 
Study of black and white adults showed that elevated hs-CRP at baseline was associated with future insulin 
resistance, as measured by HOMA-IR, after accounting for race, sex, age, BMI, smoking, alcohol drinking, and 
follow-up  years24. This is also consistent with previous studies that reported associations between hs-CRP and 
insulin resistance among specific populations. In an occupational cohort of 10,308 British civil servants in the 
Table 1.  General characteristics of the study population by insulin resistance status, as estimated by TyG 
index, Korea National Health and Nutrition Examination Survey 2016–2018. Boldface P-values indicate 
statistical significance. ªTyG index was calculated by the formula ln[fasting triglycerides (mg/dL) × fasting 
glucose (mg/dL)/2]. *P values were obtained by Chi-square test or Fisher’s exact test.
Insulin resistance (TyG  indexa)
Men (n = 5706)
P value*
Women (n = 6707)
P value*
Total No (< 8.706) Yes (≥ 8.706) Total No (< 8.355) Yes (≥ 8.355)
N % N % N % N % N % N %
Serum hs-CRP level < 0.0001 < 0.0001
Low 2715 47.58 1564 57.61 1151 42.39 3343 49.84 2046 61.20 1297 38.80
High 2991 52.42 1287 43.03 1704 56.97 3364 50.16 1306 38.82 2058 61.18
Age in years < 0.0001 < 0.0001
20–29 781 13.69 518 66.33 263 33.67 880 13.12 656 74.55 224 25.45
30—39 1101 19.30 537 48.77 564 51.23 1315 19.61 835 63.50 480 36.50
40—49 1153 20.21 465 40.33 688 59.67 1525 22.74 809 53.05 716 46.95
50—59 1037 18.17 445 42.91 592 57.09 1367 20.38 562 41.11 805 58.89
 ≥ 60 1634 28.64 886 54.22 748 45.78 1620 24.15 490 30.25 1130 69.75
Monthly household income 0.070 < 0.0001
Low 788 13.81 421 53.43 367 46.57 989 14.75 349 35.29 640 64.71
Mid-low 1325 23.22 661 49.89 664 50.11 1638 24.42 740 45.18 898 54.82
Mid-high 1677 29.39 849 50.63 828 49.37 1963 29.27 1021 52.01 942 47.99
High 1916 33.58 920 48.02 996 51.98 2117 31.56 1242 58.67 875 41.33
Educational level 0.001 < 0.0001
High school diploma or below 3093 54.21 1594 51.54 1499 48.46 3960 59.04 1665 42.05 2295 57.95
College graduate or above 2613 45.79 1257 48.11 1356 51.89 2747 40.96 1687 61.41 1060 38.59
Region 0.974 0.0002
Urban 4732 82.93 2361 49.89 2371 50.11 5675 84.61 2892 50.96 2783 49.04
Rural 974 17.07 490 50.31 484 49.69 1032 15.39 460 44.57 572 55.43
BMI (kg/m2) < 0.0001 < 0.0001
Underweight or normal 
(< 23.0) 1899 33.28 1260 66.35 639 33.65 3566 53.17 2265 63.52 1301 36.48
Overweight or obese (≥ 23.0) 3807 66.72 1591 41.79 2216 58.21 3141 46.83 1087 34.61 2054 65.39
Smoking status < 0.0001 < 0.0001
Non-smoker 3637 63.74 1990 54.72 1647 45.28 6303 9398 3196 50.71 3107 49.29
Current smoker 2069 36.26 861 41.61 1208 58.39 404 6.02 156 38.61 248 61.39
Drinking status < 0.0001 <0.0001
Non-drinker 677 11.86 394 58.20 283 41.80 1405 20.95 595 42.35 810 57.65
Drinker 5029 88.14 2457 48.86 2572 51.14 5302 79.05 2757 52.00 2545 48.00
Physical activity 0.001 < 0.0001
Active 2740 48.02 1430 52.19 1310 47.81 2939 43.82 1598 54.37 1341 45.63
Inactive 2966 51.98 1421 47.91 1545 52.09 3768 56.18 1754 46.55 2014 53.45
Hypertension < 0.0001 < 0.0001
No 3901 68.37 2115 54.22 1786 45.78 5280 78.72 2951 55.89 2329 44.11
Yes 1805 31.63 736 40.78 1069 59.22 1427 21.28 401 28.10 1026 71.90
Dyslipidemia < 0.0001 < 0.0001
No 3228 56.57 2189 67.81 1039 32.19 3479 51.87 2379 68.38 1100 31.62
Yes 2478 43.43 662 26.72 1816 73.28 3228 48.13 973 30.14 2255 69.86
Cardiovascular diseases 0.207 < 0.0001
No 5438 95.30 2707 49.78 2731 50.22 6552 97.69 3312 50.55 3240 49.45
Yes 268 4.70 144 53.73 124 46.27 155 2.31 40 25.81 115 74.19
Total participants 5706 100.0 2851 49.96 2855 50.04 6707 100.00 3352 49.98 3355 50.02
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Whitehall II study, baseline subclinical inflammation biomarker levels were related to subsequent five-year 
changes in IR among non-diabetic  individuals25. In contrast, a cross-sectional study of men aged 40–80 years 
did not find a significant association between CRP level and insulin resistance, after controlling for body com-
position parameters.
Additionally, we observed that the combined effects of systemic inflammation and BMI were greater than the 
sum of their individual impacts. Relative to individuals with low hs-CRP and BMI < 23, those with concomitant 
systemic inflammation and overweight/obese status had up to three-times greater odds of being insulin resist-
ant. In our study, there was a relatively modest synergistic interaction between elevated serum hs-CRP levels 
and overweight/obese status on the OR of insulin resistance, and approximately 24% and 29% of effects were 
attributable to additive interactions in men and women, respectively. These results are in accordance with the 
Table 2.  General characteristics of the study population according to sex-specific median hs-CRP levels. 
Boldface P-values indicate statistical significance. *P values were obtained by Chi-square test or Fisher’s exact 
test.
Serum hs-CRP level
Men (n = 5706)
P value*










N % N % N % N %
Age in years < 0.0001 < 0.0001
20–29 454 16.72 327 10.93 534 15.97 346 10.29
30–39 527 19.41 574 19.19 704 21.06 611 18.16
40–49 575 21.18 578 19.32 840 25.13 685 20.36
50–59 451 16.61 586 19.60 632 18.91 735 21.85
≥ 60 708 26.08 926 30.96 633 18.94 987 29.34
Monthly household income  < 0.0001  < 0.0001
Low 313 11.53 475 15.88 392 11.73 597 17.75
Mid-low 604 22.25 721 24.11 765 22.88 873 25.95
Mid-high 829 30.53 848 28.35 1007 30.12 956 28.42
High 969 35.69 947 31.66 1179 35.27 938 27.88
Educational level  < 0.0001  < 0.0001
High school diploma or below 1385 51.01 1708 57.10 1850 55.34 2110 62.72
College graduate or above 1330 48.99 1283 42.90 1493 44.66 1254 37.28
Region 0.001 0.0004
Urban 2297 84.60 2435 81.41 2881 86.18 2794 83.06
Rural 418 15.40 556 18.59 462 13.82 570 16.94
BMI (kg/m2)  < 0.0001  < 0.0001
Underweight or normal (< 23.0) 1121 41.29 778 26.01 2264 67.72 1302 38.70
Overweight or obese (≥ 23.0) 1594 58.71 2213 73.99 1079 32.28 2062 61.30
Smoking status 0.003 0.243
Non-smoker 1785 65.75 1852 61.92 3153 94.32 3150 93.64
Current smoker 930 34.25 1139 38.08 190 5.68 214 6.36
Drinking status 0.083  < 0.0001
Non-drinker 301 11.09 376 12.57 597 17.86 808 24.02
Drinker 2414 88.91 2615 87.43 2746 82.14 2554 75.98
Physical activity 0.022 0.001
Active 1347 49.61 1393 46.57 1536 45.95 1403 41.71
Inactive 1368 50.39 1598 53.43 1807 54.05 1961 58.29
Hypertension  < 0.0001  < 0.0001
No 1976 72.78 1925 64.36 2827 84.56 2453 72.92
Yes 739 27.22 1066 35.64 516 15.44 911 27.08
Dyslipidemia  < 0.0001  < 0.0001
No 1707 62.87 1521 50.85 2097 62.73 1382 41.08
Yes 1008 37.13 1470 49.15 1246 37.27 1982 58.92
Cardiovascular diseases 0.346 0.008
No 2595 95.58 2843 95.05 3286 98.29 3266 97.09
Yes 120 4.42 148 4.95 57 1.71 98 2.91
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findings of an earlier study that identified a significant interaction between body size and serum hs-CRP on 
insulin resistance in a cohort of Japanese adults aged 35–69 years23.
Mechanistically, systemic inflammation and obesity may affect insulin resistance via several pathways. Nota-
bly, fat accumulation in the liver or adipose tissues has been found to induce the production of pro-inflammatory 
cytokines, such as tumour necrosis factor alpha (TNF-α) and IL-626,27. These adipocyte-produced cytokines 
stimulate hepatic CRP production and activation of the innate immune  system28,29. An in vivo in mice found that 
chronic exposure to IL-6 impairs insulin receptor signalling in primary  hepatocytes30. Therefore, increased TNF-α 
and/or IL-6 secretion may be responsible for the observed relationship between elevated serum hs-CRP and IR. 
Furthermore, inflammation may promote the development of IR by triggering the development of hypertension 
by influencing platelet adhesion, aggregation, and oxidant  production31. Moreover, prior studies suggest that 
subclinical inflammation leads to diminished nitric oxide synthesis in endothelial cells and endothelial dysfunc-
tion, which promotes  IR32–35. Additional studies are required to clarify the precise mechanisms and establish the 
causal effects of systemic inflammation and obesity on insulin sensitivity.
The present study has several strengths. First, this study features a nationally representative sample that sur-
veyed a large sample of Korean adults using standardised questionnaires and laboratory procedures. Hence, the 
findings are likely to be generalizable to the overall Korean population. Furthermore, we attempted to minimise 
potential bias due to reverse causation by excluding participants with a diabetes and those who use anti-diabetic 
Table 3.  Age- and multivariable-adjusted ORs and 95% CIs for insulin resistance according to serum high-
sensitivity CRP level and BMI in separate models, KNHANES 2016–2018. a Adjusted for age. b Adjusted for age, 
region, household income, educational level, smoking status, drinking status, physical activity, hypertension, 
dyslipidemia, cardiovascular disease. OR odds ratio, CI confidence interval, BMI body mass index.
Age  adjusteda Multivariable  adjustedb




High 1.78 (1.60–1.98) 1.57 (1.39–1.76)
BMI
Underweight or normal (< 23.0) 1.00 1.00




High 2.26 (2.04–2.51) 1.84 (1.65–2.05)
BMI
Underweight or normal (< 23.0) 1.00 1.00
Overweight or obese (≥ 23.0) 2.74 (2.47–3.04) 2.14 (1.91–2.39)
Figure 1.  Additive interaction of high hs-CRP and BMI on insulin resistance.
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medication. However, our results should be considered in light of certain limitations. First, important questions 
that arises from these observations is whether adiposity-induced inflammation precedes IR or vice versa, and 
whether this relationship is bidirectional, particularly in the pathophysiology of T2DM. A cross-sectional study 
design with a single assessment of hs-CRP limits inferences regarding the temporal relationship between hs-
CRP and IR. Therefore, prospective cohort studies may provide a better context for answering these questions. 
Second, the self-reporting of health-related factors and history of cardiovascular diseases could have led to recall 
bias. Lastly, although a wide spectrum of confounders was included in the adjustments, the presence of certain 
residual or undetected confounding factors cannot be completely ruled out.
In summary, our study provides further evidence that concomitant systemic inflammation and overweight/
obesity may synergistically contribute to IR, such that prevention strategies for IR that aim to reduce both 
systematic inflammation and BMI may exceed the benefits that are expected from targeting these risk factors 
separately. These findings need to be confirmed in future longitudinal prospective studies to establish causality 
between systemic inflammation, obesity, and IR.
Material and methods
Study population. The current study is based on data from the 2016–2018 Korean National Health and 
Nutrition Examination Survey (KNHANES)36. In brief, the KNHANES is a population-based cross-sectional 
study designed to assess the health and nutritional status of people residing in South Korea. The survey included 
a stratified multistage probability sample that is representative of the non-institutionalized civilian population, 
aged one year or above. The three major components of the KNHANES are health interviews, health examina-
tions, and nutrition surveys. The KNHANES interview includes detailed questions on demographic, socioeco-
nomic, dietary, and health-related characteristics. The health examination component comprises medical, den-
tal, and physiological measurements, as well as laboratory tests administered by trained medical personnel. The 
KNHANES survey protocols were approved by the Institutional Review Board of the Korea Centers for Disease 
Control and Prevention (IRB No. 2018-01-03-P-A), and the study complied with the Declaration of Helsinki for 
medical research involving human subjects. Informed consent was obtained from all participants.
Of the 24,269 participants (men: 11,071; women: 13,198) who participated in the 2016–2018 survey, we 
restricted our analysis to include adults aged 20 years or older. Exclusion criteria included those with a previous 
diagnosis of diabetes, individuals who were using anti-diabetic medication, or pregnant women (N = 16,638, men: 
7198; women: 9440). After excluding those with missing data on IR status or other covariates, 12,413 participants 
(men: 5706; women: 6707) were analysed.
Definition of insulin resistance. The main study outcome was IR, as measured by the triglyceride-glucose 
index (TyG index)37. The TyG index was calculated according to the following formula: log [fasting triglyceride 
(mg/dL) × fasting glucose (mg/dL)/2]. The TyG index has been proposed as a simple and clinically useful sur-
rogate for  IR18,38,39. As no cut-off points have been suggested in the literature, sex-specific median values (men: 
8.076, women: 8.355) were used to dichotomise the continuous TyG index variable into insulin-sensitive and 
insulin-resistant groups.
Laboratory measures. Blood samples were drawn from the antecubital vein in the morning of examinees 
who had fasted for at least eight hours. Serum hs-CRP levels were measured using an immunoturbidimetric 
assay on a Roche Cobas analyser. The subjects were dichotomised into “high” and “low” categories, based on 
sex-specific median hs-CRP values. The median hs-CRP cut-off values were 0.60 mg/L in men and 0.50 mg/L 
in women.
All other biochemical parameters, including triglycerides (TG), total cholesterol (TC), and fasting blood 
glucose (FBG) were measured immediately and detected enzymatically using an automatic chemistry analyser 
(Hitachi 7600, Hitachi Ltd., Tokyo, Japan). Low-density lipoprotein cholesterol (LDL-C) and high-density lipo-
protein cholesterol (HDL-C) levels were measured using homogeneous enzymatic colourimetric methods.
Other covariates. All potential confounding variables were selected based on prior knowledge of the exist-
ing  literature40–42. Standardised questionnaires were administered by well-trained interviewers to collect infor-
mation on age, sex, socioeconomic characteristics, and health-related risk factors. Participants, based on age, 
were categorised into the following groups: 20–29, 30–39, 40–49, 50–59, and ≥ 60 years. Participants were also 
categorised by educational attainment (High school diploma or below and college graduate or above) and 
monthly household income quartiles. Residential areas were divided into urban and rural areas.
Information on smoking status, drinking status, and physical activity was also obtained. Smoking status was 
categorised as either non-smoker (including never- and former-smokers) or current smoker. Participants were 
asked about alcohol consumption as follows: In the past year, how often did you drink any type of alcoholic 
beverage? Individuals were considered current drinkers if they consumed at least one drink in the past year. 
Physical activity was defined as engagement in 150 min of moderate-intensity aerobic activity or 75 min of 
vigorous-intensity aerobic activity every week.
In KNHANES, anthropometric data were collected by well-trained personnel according to a standardised pro-
tocol. Body mass index (BMI [kg/m2]) was calculated using measurement of height and weight. A BMI < 23.0 was 
considered normal weight and a BMI greater than or equal to 23.0 was considered overweight/obese, according to 
the Asia–Pacific obesity  classification43. Following the 2015 Korean Guidelines, dyslipidemia (yes/no) was defined 
as having one or more of the following lipid abnormalities: hypercholesterolemia (total cholesterol ≥ 240 mg/dL 
or use of lipid-lowering drugs), hypertriglyceridemia (TG ≥ 200 mg/dL), hyper-low density lipoprotein (LDL) 
cholesterolemia (≥ 160 mg/dL), and hypo-high density lipoprotein (HDL)-cholesterolemia (< 40 mg/dL in men 
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and < 50 mg/dL in women)44. Hypertension (yes/no) was defined as a systolic blood pressure of 140 mmHg or 
higher, diastolic blood pressure of 90 mmHg or higher, or on antihypertensive treatment. Based on self-report, 
adults who answered ‘yes’ to the following questions were also ascertained as having cardiovascular diseases: ‘Has 
a doctor or other health professional told you have had a stroke, angina, or myocardial infarction?”.
Statistical analyses. Statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, 
NC, USA). For descriptive purposes, variables were summarised in frequencies, and sample proportions of cat-
egorical variables were obtained. Chi-square or Fisher’s exact tests were used to determine whether the distribu-
tion of categorical covariates of insulin-sensitive participants differed from the distributions of insulin-resistant 
individuals. To examine associations of hs-CRP and body mass index with IR, odds ratios (ORs) and 95% con-
fidence intervals were estimated using logistic regression. Age, region, monthly household income, educational 
level, smoking status, drinking status, physical activity, hypertension, dyslipidemia, and self-reported diagnosis 
of cardiovascular diseases were adjusted, when appropriate.
Additionally, we investigated the presence of biological interactions on an additive scale, that is, whether the 
combination of high hs-CRP and BMI poses greater risk than the sum of their independent effects. This was 
evaluated using three indices of additive interaction: RERI (the relative excess risk due to interaction), AP (the 
proportion attributable to interaction), and the synergy index (SI)45,46. The RERI is defined as the additional 
risk due to interaction, which is calculated as the difference between the expected risk based on the addition 
of the ORs of the separate effects of the two risk factors under exposure and the observed risk in the doubly 
exposed group: RERI = OR11-OR10-OR01 + 1, where  OR11 refers to the odds ratio of insulin resistance for high 
hs-CRP combined with BMI ≥ 23;  OR10 is the OR of insulin resistance for elevated serum hs-CRP with BMI < 23; 
and  OR01 represents exposure to BMI ≥ 23 only. The AP is interpreted as the proportion of disease that is due 
to interaction among individuals with both exposures: AP = RERI/OR11. The SI refers to the excess risk from 
both exposures when there is interaction, relative to the risk from exposure without interaction: SI = (OR11–1)/
[(OR01–1) + (OR10–1)]). The resulting confidence intervals of RERI > 0 or AP > 0 or SI > 1 were indicative of posi-
tive departure from additivity, or synergistic interaction of the effects from two exposures on insulin resistance. 
In these analyses, adjustments were made for the same sets of potential confounders as described for the logistic 
regression models. All statistical test with a 2-tailed P < 0 0.05 were considered statistically significant.
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